Belgian drugmaker UCB SA has agreed to settle a lawsuit with generic drugmaker Mylan, which sought to make generic versions of UCB SA's epilepsy drug Keppra. The settlement requires UCB to be approved for "pediatric exclusivity" from the FDA before Mylan can begin selling its version of the drug in November 2008.

Full Story:

Related Summaries